MNTA has been the topic of a number of other research reports. BidaskClub lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 9th. Cantor Fitzgerald reiterated a “buy” rating and issued a $25.00 target price on shares of Menlo Therapeutics in a research report on Thursday, May 2nd. Finally, Zacks Investment Research lowered Farmers & Merchants Bancorp, Inc. (OH) from a “hold” rating to a “strong sell” rating in a research report on Thursday, May 9th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $22.23.
Momenta Pharmaceuticals stock traded down $0.55 during trading hours on Friday, reaching $9.60. The stock had a trading volume of 326,123 shares, compared to its average volume of 538,663. The company has a market capitalization of $946.68 million, a P/E ratio of -4.73 and a beta of 2.13. The stock has a 50 day moving average of $11.83. Momenta Pharmaceuticals has a 52 week low of $9.55 and a 52 week high of $32.20.
Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.01). Momenta Pharmaceuticals had a negative return on equity of 43.98% and a negative net margin of 231.49%. The business had revenue of $4.11 million for the quarter, compared to analysts’ expectations of $10.12 million. During the same quarter in the previous year, the firm posted ($0.63) EPS. Momenta Pharmaceuticals’s revenue was down 15.3% on a year-over-year basis. Research analysts predict that Momenta Pharmaceuticals will post -1.79 EPS for the current year.
In other Momenta Pharmaceuticals news, SVP Santiago Arroyo sold 2,531 shares of the company’s stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $15.00, for a total value of $37,965.00. Following the sale, the senior vice president now owns 19,272 shares in the company, valued at approximately $289,080. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Jo Ann Beltramello sold 13,672 shares of the company’s stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $15.00, for a total value of $205,080.00. Following the completion of the sale, the insider now owns 68,494 shares in the company, valued at approximately $1,027,410. The disclosure for this sale can be found here. In the last quarter, insiders sold 63,784 shares of company stock worth $868,941. 3.40% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the business. Quantamental Technologies LLC purchased a new stake in Momenta Pharmaceuticals in the 1st quarter worth approximately $68,000. Marshall Wace North America L.P. purchased a new stake in Momenta Pharmaceuticals in the 1st quarter worth approximately $130,000. Amalgamated Bank purchased a new stake in Momenta Pharmaceuticals in the 4th quarter worth approximately $136,000. CWM Advisors LLC boosted its position in Momenta Pharmaceuticals by 17.2% in the 2nd quarter. CWM Advisors LLC now owns 13,780 shares of the biotechnology company’s stock worth $172,000 after purchasing an additional 2,020 shares in the last quarter. Finally, Everence Capital Management Inc. purchased a new stake in Momenta Pharmaceuticals in the 1st quarter worth approximately $214,000. Institutional investors and hedge funds own 97.43% of the company’s stock.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.
See Also: Capital Gains Distribution
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.